Geron Corporation (GERN)

Geron Corporation shares surged 14.7% after the company provided its first full-year RYTELO revenue guidance of $220 million to $240 million and reported a narrowed first-half net loss. The stock closed at $1.48, significantly below analyst consensus targets, reflecting deep disagreement over RYTELO's commercial ramp and the company's path to profitability. The future performance of RYTELO will be crucial in determining if the stock's "undervalued" narrative holds, especially given the company's reliance on a single product and potential future financing needs.

This article from TradingView lists various ETFs that include Geron Corporation (GON) stocks in their portfolios. It provides detailed financial data for each ETF, such as market value, weight of GON stock, issuer, management style, expense ratio, assets under management (AUM), price, and 3-year NAV total return. The ETFs cover different investment strategies, including passive and active management, and focus on sectors like healthcare, biotechnology, small-cap, and total market.

Edmond DE Rothschild Holding S.A. has acquired a new position in Geron Corporation, purchasing 2,330,000 shares valued at approximately $2,982,000. This makes Edmond DE Rothschild Holding S.A. an owner of about 0.36% of Geron. Other institutional investors like RA Capital Management L.P., BlackRock Inc., and Vanguard Group Inc. have also significantly modified their holdings in the biopharmaceutical company.

Geron (GERN) has shown positive stock performance recently following its Q2 and H1 2026 earnings report and new RYTELO guidance, which provides clearer revenue visibility. The company's valuation narrative suggests it is 53.2% undervalued, with a fair value of $3.40 per share, driven by aggressive revenue expansion and pipeline catalysts like myelofibrosis expansion and EU approvals. However, the valuation heavily depends on RYTELO's execution and the telomerase pipeline, making it susceptible to setbacks.

Analyst Consensus Target has updated its fair value for Geron (GERN) to $4.25 from $3.40, driven by improved assumptions for revenue growth (44.30% vs 37.82%), profit margin (38.05% vs 22.97%), and a lower future P/E of 14.80. The company also issued earnings guidance for 2026, projecting RYTELO net product revenue between US$220 million and US$240 million. These revised metrics indicate a stronger margin outlook and a more favorable valuation for Geron.